Myocea

Myocea is a private biotechnology company focused on skeletal muscle biology, neuromuscular disorders, and regenerative medicine. The company originated from Genea Biocells and uses a proprietary transgene-free skeletal muscle differentiation platform to generate satellite cells, myoblasts, and 2D/3D muscle models for disease modeling, screening, and therapeutic development. Its lead therapeutic program is GBC0905 (rebastinib), a small-molecule candidate for facioscapulohumeral muscular dystrophy (FSHD), for which orphan drug designation was previously granted by the FDA. Myocea is also developing regenerative satellite-cell-based approaches and muscle system models relevant to spinal muscular atrophy and other muscle diseases. Beyond therapeutics, the company presents capabilities spanning organoid-style muscle systems and non-medical muscle tissue applications such as cultivated meat.